“IT-139 (Intezyne Technologies) downregulates the stress-induction of GRP78 in cancer cells, a critical cell survival protein that is associated with both drug resistance and tumor proliferation,” Suzanne Bakewell, PhD, vice president and program manager for IT-139, said in a company-issued press release. “GRP78 expression is not elevated in the same way in normal cells, leaving them unaffected.” Read more . . .
The FDA granted orphan drug designation to IT-139 for the treatment of pancreatic cancer, according to the drug’s manufacturer.